Literature DB >> 10072733

Tumor necrosis factor-alpha decreases the phosphorylation levels of phospholamban and troponin I in spontaneously beating rat neonatal cardiac myocytes.

T Yokoyama1, M Arai, K Sekiguchi, T Tanaka, T Kanda, T Suzuki, R Nagai.   

Abstract

The tumor necrosis factor (TNF) alpha level is elevated in patients with advanced heart failure, and the phosphorylation of contractile regulatory proteins is reduced in the human heart. We hypothesized that TNFalpha affects the phosphorylation of proteins involved in regulating contraction; phospholamban (PLB), myosin light chain 2 (MLC2) and troponin I (TnI). Spontaneously beating rat neonatal cardiac myocytes, prelabelled with [32P]orthophosphate, were treated with TNFalpha for 30 min, and stimulated with isoproterenol for 5 min. 32P-labelled myofibrillar proteins were isolated by 15% SDS-PAGE. Baseline phosphorylation levels of PLB, TnI and an unknown 23kDa phosphoprotein were decreased by TNFalpha in a dose-dependent manner. Moreover, TNFalpha attenuated the phosphorylation levels of PLB and TnI increased by a concentration of 0.01 microM isoproterenol, but not by 1 microM of isoproterenol. Although TNFalpha had no effect on the cAMP content or cAMP-dependent protein kinase activity in the presence or absence of isoproterenol, an inverse relationship was observed between the concentration of TNFalpha and the cGMP content in cardiac myocytes, and treatment with TNFalpha resulted in a concentration-dependent increase in type 2A protein phosphatase activity. The observation that TNFalpha decreases phosphorylation levels of PLB and TnI in cardiac myocytes suggests that the reduction of these protein phosphorylation levels is partially responsible for alterations of intracellular Ca2+-cycling and the force of contraction in TNF alpha-treated cardiac myocytes. Furthermore, TNFalpha reduces myocyte contraction and protein phosphorylation states possibly via cAMP-independent mechanisms, at least in part, by the activation of type 2A protein phosphatase.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10072733     DOI: 10.1006/jmcc.1998.0863

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  6 in total

1.  Inhibition of sarcoplasmic reticular function by chronic interleukin-6 exposure via iNOS in adult ventricular myocytes.

Authors:  Xin-Wen Yu; Qian Chen; Richard H Kennedy; Shi J Liu
Journal:  J Physiol       Date:  2005-04-21       Impact factor: 5.182

2.  A comparative study of myocardial injury during conventional and endovascular aortic aneurysm repair: measurement of cardiac troponin T and plasma cytokine release.

Authors:  M C Barry; J M Hendriks; L C van Dijk; P Pattynama; D Poldermans; D Bouchier Hayes; H van Urk; M R H M van Sambeek
Journal:  Ir J Med Sci       Date:  2009-02-17       Impact factor: 1.568

3.  Overexpression of protein phosphatase 5 in the mouse heart: Reduced contractility but increased stress tolerance - Two sides of the same coin?

Authors:  Ulrich Gergs; Tina Jahn; Franziska Werner; Carolin Köhler; Friedrich Köpp; Claudia Großmann; Joachim Neumann
Journal:  PLoS One       Date:  2019-08-19       Impact factor: 3.240

Review 4.  Novel Insights into the Role of HDL-Associated Sphingosine-1-Phosphate in Cardiometabolic Diseases.

Authors:  Elena M G Diarte-Añazco; Karen Alejandra Méndez-Lara; Antonio Pérez; Núria Alonso; Francisco Blanco-Vaca; Josep Julve
Journal:  Int J Mol Sci       Date:  2019-12-12       Impact factor: 5.923

5.  Cardiac force-frequency relationship and frequency-dependent acceleration of relaxation are impaired in LPS-treated rats.

Authors:  Olivier Joulin; Sylvestre Marechaux; Sidi Hassoun; David Montaigne; Steve Lancel; Remi Neviere
Journal:  Crit Care       Date:  2009-02-06       Impact factor: 9.097

6.  The effects of tumor necrosis factor-alpha on systolic and diastolic function in rat ventricular myocytes.

Authors:  David J Greensmith; Mahesh Nirmalan
Journal:  Physiol Rep       Date:  2013-09-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.